CNTB · XBRL financial data

Connect Biopharma Holdings financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CNTB's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	0	26	0
Research and development	—	—	53	29	38
General and administrative	—	—	16	19	20
Total operating expenses	—	—	69	48	58
Operating income (loss)	—	—	(69)	(22)	(58)
Other income (expense)	—	—	2	3	1
Income tax expense (benefit)	—	—	0	0	0
Net income (loss)	—	—	(62)	(16)	(55)
Earnings per share, basic USD per share	—	—	(1.13)	(0.28)	(1.00)
Earnings per share, diluted USD per share	—	—	(1.13)	(0.28)	(1.00)
Weighted average shares, basic millions of shares	—	—	55	55	56
Weighted average shares, diluted millions of shares	—	—	55	55	56
Research and development millions of CNY	518	652	—	—	—
Operating profit (loss) millions of CNY	(631)	(806)	—	—	—
Profit (loss) millions of CNY	(1,307)	(797)	—	—	—
Earnings per share, basic CNY per share	(25.00)	(14.50)	—	—	—
Earnings per share, diluted USD per share	(3.88)	(2.10)	(1.08)	—	—

Fiscal years (CNTB's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	—	79	106	78	38
Short-term investments	—	—	13	15	6
Accounts receivable	—	—	0	1	0
Prepaid and other current assets	—	—	4	2	7
Total current assets	—	—	123	97	51
Property and equipment, net	—	—	4	4	4
Right-of-use asset	—	—	0	0	1
Total assets	—	—	127	101	56
Accounts payable	—	—	2	0	2
Accrued liabilities	—	—	9	8	11
Total current liabilities	—	—	25	8	14
Lease liability, non-current	—	—	0	0	0
Total liabilities	—	—	26	9	14
Accumulated deficit	—	—	(330)	(345)	(401)
Total stockholders' equity	—	158	101	92	42
Total liabilities and equity	—	—	127	101	56
Common shares outstanding (cover page) millions of shares	55	55	55	55	57
Cash and cash equivalents	268	79	106	—	—
Total current assets	275	156	121	—	—
Total assets	291	174	126	—	—
Total current liabilities	18	16	24	—	—
Total liabilities	19	17	25	—	—
Total equity millions of CNY	1,736	1,097	—	—	—
Total equity and liabilities	291	174	126	—	—

Fiscal years (CNTB's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	—	(62)	(16)	(55)
Stock-based compensation	—	—	5	7	4
Depreciation and amortization	—	—	1	1	1
Net cash from operating activities	—	—	(48)	(24)	(51)
Purchases of property and equipment	—	—	0	1	0
Net cash from investing activities	—	—	75	(3)	10
Net cash from financing activities	—	—	0	0	1
Net change in cash	—	—	27	(27)	(40)
Net cash from operating activities millions of CNY	(545)	(680)	—	—	—
Net cash from investing activities millions of CNY	(34)	(571)	—	—	—
Net cash from financing activities millions of CNY	1,316	(1)	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Connect Biopharma Holdings	27	2.8	(16)*	63.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5.7	not reported	(1.2)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Actinium Pharmaceuticals	36	35	(5.2)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	197	19	(59)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.